Price to FCFE (P/FCFE)

Free Cash Flow to Equity (FCFE)
P to FCFE Ratio, Current
P to FCFE Ratio, Historical

Paying user area

Try for free

Allergan PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan PLC for $22.49.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Free Cash Flow to Equity (FCFE)

Allergan PLC, FCFE calculation

US$ in thousands

	12 months ended:	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
	Net income (loss) attributable to shareholders
	Income attributable to noncontrolling interest
	Net noncash charges
	Changes in assets and liabilities, net of effects of acquisitions
	Net cash provided by operating activities
	Additions to property, plant and equipment
	Additions to product rights and other intangibles
	Proceeds from sales of property, plant and equipment
	Proceeds from borrowings of long-term indebtedness, including credit facility
	Payments on debt, including capital lease obligations and credit facility
	Debt issuance and other financing costs
	Free cash flow to equity (FCFE)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Download chart

Item	Description	The company
FCFE	Free cash flow to equity is the cash flow available to Allergan PLC equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made.	Allergan PLC FCFE decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.

Price to FCFE Ratio, Current

Allergan PLC, current P/FCFE calculation, comparison to benchmarks

No. shares of common stock outstanding
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands)
FCFE per share
Current share price (P)
Valuation Ratio
P/FCFE
Benchmarks
P/FCFE, Competitors¹
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
P/FCFE, Sector
Pharmaceuticals, Biotechnology & Life Sciences
P/FCFE, Industry
Health Care

Based on: 10-K (reporting date: 2019-12-31).

¹ Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Price to FCFE Ratio, Historical

Allergan PLC, historical P/FCFE calculation, comparison to benchmarks

		Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Free cash flow to equity (FCFE) (in thousands)²
	FCFE per share³
	Share price^1, 4
	Valuation Ratio
	P/FCFE⁵
	Benchmarks
	P/FCFE, Competitors⁶
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Danaher Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Thermo Fisher Scientific Inc.
	P/FCFE, Sector
	Pharmaceuticals, Biotechnology & Life Sciences
	P/FCFE, Industry
	Health Care

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

¹ Data adjusted for splits and stock dividends.

² See details »

³ 2019 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =

⁴ Closing price as at the filing date of Allergan PLC Annual Report.

⁵ 2019 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =

⁶ Click competitor name to see calculations.